Parasites and Biliary stones

References ١٦٠
Harinasuta C and Harinasuta T (1984): Opisthorchis viverrini: life cycle,
intermediate hosts, transmission to man and geographical distribution in
Thailand. Arzneimittelforschung 34, 1164–1167.
Harinasuta T, Riganti M and Bunnag D (1984): Opisthorchis viverrini
infection: pathogenesis and clinical features.Arzneimittelforschung. 34,
(9B):1167–1169.
Harris A, Chan AC and Torres-Viera C (1999): Meta analysis of antibiotic
prophylaxis in Endoscopic Retrograde Cholangiopancreatography
(ERCP). Endoscopy; 31: 718-24.
Haswell-Elkins MR, Sithithaworn P, Mairiang E, Elkins DB,
Wongratanacheewin S, Kaewkes S, Mairiang, P, (1991): Immune
responsiveness and parasite-specific antibody levels in human
hepatobiliary disease associated with Opisthorchis viverrini infection.
Clin. Exp. Immunol. 84, 213–218.
Hauser SC and Bynum TE (1984):Abnormalities on ERCP in a case of
Hawes RH (2002): Diagnostic and therapeutic uses of ERCP in pancreatic and
biliary tract malignancies. Gastrointest Endosc;56(Suppl 6): S201-5.
Hawes RH and Sherman S (1995): Choledocholithiasis. In:
Gastroenterology. 5th edition, Chapter. 142; 2745.
Heresi G and Cleary TG (1997): Giardia. Pediatr Rev 18:243-247.
Heuman DM (2006):Cholelithiasis,e.medicine from,Gastroenterology
magazine. WWW. emedicine. Com
Hewitt RG,Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R,
Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z,
Walawander AL, Flanigan TP, Bender JF, (2000): AIDS Clinical Trial
Group, Paromomycin: no more effective than placebo for treatment of